ACCC logo
Facebook  LinkedIn  Twitter  ACCC Youtube Channel  ACCCBuzz blog

Association of Community Cancer Centers

The leading education and advocacy organization for the multidisciplinary cancer team

ACCCBuzz Blog  Find a Cancer Program  Log in to MyNetwork

Home > Mediaroom > Press Releases > 2016 > ACCC Honored to Contribute to National Academies Immunotherapy Policy Workshop Proceedings

ACCC Media Advisory

CONTACT: Lori Gardner, Senior Director
Communications & Marketing
301.984.9496 ext. 226

FOR IMMEDIATE RELEASE:
August 1, 2016

ACCC Honored to Contribute to National Academies Immunotherapy Policy Workshop Proceedings

Statement from ACCC President Jennie R. Crews, MD, MMM, FACP

Recent advances in immunotherapy have launched an exciting new era for cancer treatment. However, to expand patient access to these groundbreaking therapies the oncology community must overcome evolving implementation and policy challenges. In support of efforts to identify and address these emerging issues, Association of Community Cancer Centers (ACCC) joined with other invited participants in a workshop on Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment convened by the National Cancer Policy Forum of the National Academies of Sciences, Engineering, and Medicine.* Participants examined state-of-the-science clinical challenges and policy issues around these promising new therapies.

Representatives from the Institute for Clinical Immuno-Oncology (ICLIO), an institute of ACCC, were honored to join with representatives from the research, clinician, patient, government agency, pharmaceutical industry, and healthcare payer communities—all united in an effort to bring forward understanding of challenges to realizing the potential of these new therapies.

As reported in the workshop proceedings, Lee Schwartzberg, MD, FACP, Chair of the ICLIO Advisory Committee, brings to light critical educational challenges clinicians are facing in adopting these new therapies, including lack of information about specific therapies, few experts to consult with, and a lack of immunotherapy education and training for their staff and peers. ICLIO’s vital role in helping to close these educational gaps for all members of the multidisciplinary care teams providing immunotherapy in the community was also noted.

As we work to bring immunotherapy to patients close in their home communities, ACCC and the Institute for Clinical Immuno-Oncology look forward to continued collaboration with all stakeholders in advancing quality, patient-centered cancer care.

*In March 2016, the Institute of Medicine (IOM) was renamed the National Academies of Sciences, Engineering, and Medicine (the Academies) Health and Medicine Division (HMD).

About the Association of Community Cancer Centers
The Association of Community Cancer Centers (ACCC) is the leading advocacy and education organization for the multidisciplinary cancer care team. More than 23,000 cancer care professionals from over 2,000 hospitals and practices nationwide are affiliated with ACCC. It is estimated that 65 percent of the nation's cancer patients are treated by a member of ACCC. Providing a national forum for addressing issues that affect community cancer programs, ACCC is recognized as the premier provider of resources for the entire oncology care team. Our members include medical and radiation oncologists, surgeons, cancer program administrators and medical directors, senior hospital executives, practice managers, pharmacists, oncology nurses, radiation therapists, social workers, and cancer program data managers. For more information, visit ACCC's website at www.accc-cancer.org. Follow us on Facebook, Twitter, LinkedIn, and read our blog, ACCCBuzz.

Copyright © 2017 Association of Community Cancer Centers. All Rights Reserved.
1801 Research Boulevard, Suite 400, Rockville, MD 20850  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US